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Nasal high-flow therapy for newborn infants in special care nurseries
Abstract
Background: Nasal high-flow therapy is an alternative to nasal continuous positive airway pressure (CPAP)
as a means of respiratory support for newborn infants. The efficacy of high-flow therapy in nontertiary special
care nurseries is unknown.
Methods: We performed a multicenter, randomized, noninferiority trial involving newborn infants (age;
gestational age, ≥31 weeks) in special care nurseries in Australia. Newborn infants with respiratory distress
and a birth weight of at least 1200 g were assigned to treatment with either high-flow therapy or CPAP. The
primary outcome was treatment failure within 72 hours after randomization. Infants in whom high-flow
therapy failed could receive CPAP. Noninferiority was determined by calculating the absolute difference in the
risk of the primary outcome, with a noninferiority margin of 10 percentage points.
Results: A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight, 2909 g) were
included in the primary intention-to-treat analysis. Treatment failure occurred in 78 of 381 infants (20.5%) in
the high-flow group and in 38 of 373 infants (10.2%) in the CPAP group (risk difference, 10.3 percentage
points; 95% confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treatment failure
occurred in 49 of 339 infants (14.5%) in the high-flow group and in 27 of 338 infants (8.0%) in the CPAP
group (risk difference, 6.5 percentage points; 95% CI, 1.7 to 11.2). The incidences of mechanical ventilation,
transfer to a tertiary neonatal intensive care unit, and adverse events did not differ significantly between the
groups.
Conclusions: Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a
significantly higher incidence of treatment failure than CPAP when used in nontertiary special care nurseries
as early respiratory support for newborn infants with respiratory distress. (Funded by the Australian National
Health and Medical Research Council and Monash University; HUNTER Australian
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BACKGROUND
Nasal high-flow therapy is an alternative to nasal continuous positive airway pres-
sure (CPAP) as a means of respiratory support for newborn infants. The efficacy 
of high-flow therapy in nontertiary special care nurseries is unknown.
METHODS
We performed a multicenter, randomized, noninferiority trial involving newborn 
infants (<24 hours of age; gestational age, ≥31 weeks) in special care nurseries in 
Australia. Newborn infants with respiratory distress and a birth weight of at least 
1200 g were assigned to treatment with either high-flow therapy or CPAP. The 
primary outcome was treatment failure within 72 hours after randomization. In-
fants in whom high-flow therapy failed could receive CPAP. Noninferiority was 
determined by calculating the absolute difference in the risk of the primary out-
come, with a noninferiority margin of 10 percentage points.
RESULTS
A total of 754 infants (mean gestational age, 36.9 weeks, and mean birth weight, 
2909 g) were included in the primary intention-to-treat analysis. Treatment failure 
occurred in 78 of 381 infants (20.5%) in the high-flow group and in 38 of 373 
infants (10.2%) in the CPAP group (risk difference, 10.3 percentage points; 95% 
confidence interval [CI], 5.2 to 15.4). In a secondary per-protocol analysis, treat-
ment failure occurred in 49 of 339 infants (14.5%) in the high-flow group and in 
27 of 338 infants (8.0%) in the CPAP group (risk difference, 6.5 percentage points; 
95% CI, 1.7 to 11.2). The incidences of mechanical ventilation, transfer to a ter-
tiary neonatal intensive care unit, and adverse events did not differ significantly 
between the groups.
CONCLUSIONS
Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in 
a significantly higher incidence of treatment failure than CPAP when used in non-
tertiary special care nurseries as early respiratory support for newborn infants 
with respiratory distress. (Funded by the Australian National Health and Medical 
Research Council and Monash University; HUNTER Australian and New Zealand 
Clinical Trials Registry number, ACTRN12614001203640.)
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Clinicians aim to avoid the use of mechanical ventilation through an endo-tracheal tube in newborn infants with 
respiratory distress by providing noninvasive re-
spiratory support. In Australia, infants for whom 
ongoing mechanical ventilation is indicated are 
typically transferred to a tertiary-level neonatal 
intensive care unit (NICU). Owing to potentially 
large distances between regional or rural non-
tertiary special care nurseries and metropolitan 
NICUs, a transfer may result in family disrup-
tions, with associated psychosocial and finan-
cial costs.1,2
The use of nasal continuous positive airway 
pressure (CPAP) in large Australian special care 
nurseries is beneficial and cost-effective, and it 
is associated with a lower incidence of treatment 
failure or transfer to a NICU than supplemental 
oxygen alone.3 Infants with respiratory distress 
now routinely receive CPAP in large special care 
nurseries in Australia. However, CPAP may be 
associated with an increased incidence of pneu-
mothorax,4 and experienced medical and nurs-
ing specialists are required in order to provide 
CPAP safely and effectively; this precludes its use 
in smaller special care nurseries in Australia5 
and around the world. Nasal high-flow therapy 
is an increasingly popular alternative to CPAP for 
neonatal respiratory support.6-8 High-flow therapy 
delivers heated, humidified gas at f lows of 
greater than 1 liter per minute through small 
binasal prongs. It has a simple interface that is 
easier to use and appears to be more comfort-
able than CPAP, and it is preferred by parents 
and nurses.9,10
We previously found that when used in tertiary-
level NICUs as primary respiratory support for 
preterm infants born at a gestational age of 28 
weeks 0 days to 36 weeks 6 days, high-flow 
therapy resulted in a significantly higher inci-
dence of treatment failure than did CPAP.11 How-
ever, special care nurseries have far more mature 
infants with fewer coexisting conditions than do 
NICUs; they also differ from NICUs with respect 
to medical and nursing experience and the ratio 
of providers to patients. For these reasons, high-
flow therapy may be well suited to special care 
nurseries. Since most late-preterm and term in-
fants with respiratory distress receive treatment 
in special care nurseries, data to guide respira-
tory support in this setting are relevant to many 
thousands of infants in developed countries 
each year.12 We performed the multicenter, ran-
domized, noninferiority High-Flow Use in Non-
Tertiary Centres for Early Respiratory Distress 
(HUNTER) trial in Australian special care nurs-
eries to test the hypothesis that high-flow ther-
apy is noninferior to CPAP as primary respira-
tory support for newborn infants with early 
respiratory distress.
Me thods
Trial Design and Oversight
Eligible nontertiary centers were similar to level 2 
special care nurseries as defined by the Commit-
tee on Fetus and Newborn of the American 
Academy of Pediatrics.13 The driving time from 
the centers to the closest tertiary NICU was up 
to 90 minutes. The centers routinely cared for 
infants born at or after 32 weeks of gestation, 
and occasionally they cared for infants born at 
31 weeks of gestation. At least 2000 births per 
year occurred in each center, and all centers had 
extensive experience treating infants with CPAP.
Multisite ethical approval was obtained from 
the Royal Children’s Hospital, Melbourne, Aus-
tralia, and site-specific approval was obtained 
from each center. The authors vouch for the ac-
curacy and completeness of the data and for the 
fidelity of the trial to the protocol (published 
previously14 and available with the full text of 
this article at NEJM.org). The trial had no com-
mercial support, and the manufacturers of the 
respiratory devices had no input in the trial de-
sign, data accrual, data analysis, or manuscript 
preparation and no access to the trial data.
Patients
Infants were eligible for inclusion if they were 
born at a gestational age of 31 weeks 0 days or 
later, had a birth weight of at least 1200 g, were 
less than 24 hours of age, and if the treating 
clinician determined that noninvasive respirato-
ry support was indicated, the infant had received 
supplemental oxygen for more than 1 hour, or 
both. Since CPAP treatment was the standard 
of care for respiratory distress, up to 2 hours of 
CPAP treatment was permitted while consent 
was sought. Infants were ineligible if, before 
randomization, they had received CPAP for more 
than 2 hours, had undergone endotracheal intu-
bation, had a known major congenital abnor-
mality, or if the treating clinician had decided 
that endotracheal intubation or transfer to a 
NICU was indicated.
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Consent and Randomization
The parent or parents of all participating infants 
provided written informed consent before ran-
domization. A computer-generated randomiza-
tion sequence with variable block sizes was 
used. Infants were stratified according to gesta-
tional age (<34 weeks vs. ≥34 weeks) and trial 
center. Enrolled infants who were part of mul-
tiple births underwent randomization individu-
ally. Sequentially numbered, sealed, opaque en-
velopes containing the treatment assignment 
were opened once eligibility criteria were met 
and consent was obtained.
Trial Intervention
Eligible infants were randomly assigned to treat-
ment with either high-flow therapy or CPAP 
generated with the use of an underwater “bub-
ble” system. Other aspects of care were provided 
according to local protocols, including blood gas 
analysis, chest radiography, intravenous fluids, 
and enteral feeding.
Infants assigned to the high-flow group re-
ceived an initial gas flow of 6 liters per minute 
from the Optif low Junior device (Fisher and 
Paykel Healthcare). The maximum permissible 
gas flow was 8 liters per minute, consistent with 
the maximum gas flow used in previous stud-
ies.11,15,16 Infants assigned to high-flow therapy 
who met the criteria for treatment failure could 
receive CPAP as rescue therapy, initiated at a 
pressure of 8 cm of water.
In infants who were assigned to CPAP, the 
starting pressure was 6 cm of water delivered 
through short binasal prongs or a nasal mask. 
The maximum permissible CPAP pressure was 
8 cm of water. The trial protocol recommended 
that infants from either group who met the cri-
teria for treatment failure while receiving CPAP 
be discussed with members of the local neonatal 
retrieval service and receive endotracheal intuba-
tion as appropriate. The decision to transfer the 
infant to a NICU remained with the treating 
clinician, irrespective of whether the criteria for 
treatment failure were met. High-flow therapy 
was not permitted for infants in the CPAP group. 
Guidance on weaning and discontinuation of 
respiratory support was included in the trial 
protocol.14
Trial Outcomes
The primary outcome was treatment failure 
within 72 hours after randomization. Infants 
receiving maximal support (gas flow of 8 liters 
per minute [in the high-flow group] or pressure 
of 8 cm of water [in the CPAP group]) were con-
sidered to have treatment failure if they met one 
or more of the following criteria: a fraction of 
inspired oxygen of 0.4 or higher for more than 
1 hour to maintain target oxygen saturation 
levels of 91 to 95%; a pH of less than 7.2 plus a 
partial pressure of carbon dioxide greater than 
60 mm Hg in two samples of arterial or capillary 
blood obtained at least 1 hour after commence-
ment of the assigned treatment and obtained 
1 hour apart; or two or more episodes of apnea 
for which positive-pressure ventilation was indi-
cated within a 24-hour period or six or more 
episodes for which any intervention was indi-
cated within a 6-hour period. Infants who had 
an urgent need for endotracheal intubation and 
mechanical ventilation or required transfer to a 
NICU (as determined by the treating clinician) 
were also considered to have treatment failure. 
Infants in whom respiratory management was 
escalated at the discretion of the clinician and 
who had not clearly met the criteria for treat-
ment failure were classified as having another 
reason for treatment failure.
Prespecified secondary outcomes included 
the reason or reasons for treatment failure; en-
dotracheal intubation; transfer to a NICU; the 
duration of respiratory support, supplemental 
oxygen, and hospitalization; and the cost of 
care. The complete list of prespecified secondary 
outcomes is provided in the trial protocol14 and 
in Section 2 in the Supplementary Appendix, 
available at NEJM.org. The methods for the cost-
of-care analysis are also provided Section 3 in 
the Supplementary Appendix.
Statistical Analysis
On the basis of recent admission data from par-
ticipating centers, we estimated that treatment 
failure within 72 hours after randomization 
would occur in 17% of the infants assigned to 
receive CPAP. We prespecified a noninferiority 
margin for high-flow treatment of 10 percentage 
points above the failure rate for CPAP treatment. 
Data from previous trials comparing high-flow 
therapy with CPAP in the nontertiary setting on 
which to base our sample-size calculation were 
lacking. We chose this margin of noninferiority 
on clinical grounds, taking into consideration 
that infants in whom high-flow treatment failed 
could receive CPAP treatment, which we hypoth-
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esized might obviate the need for endotracheal 
intubation. The pediatricians, neonatologists, 
and parent representatives consulted during the 
trial-design phase agreed that a treatment fail-
ure rate that was 10 percentage points higher 
with high-flow therapy than with CPAP would 
be the maximum acceptable rate. High-flow 
therapy would thus be considered noninferior to 
CPAP if the upper limit of the two-sided 95% 
confidence interval for the risk difference was 
less than 10 percentage points. For the trial to 
have 90% power, a sample of 750 infants was 
required (one-sided alpha level of 0.025).
In accordance with the prespecified statisti-
cal analysis plan (available with the protocol at 
NEJM.org), we performed both a primary inten-
tion-to-treat analysis and a secondary per-proto-
col analysis, as recommended for noninferiority 
trials.17 The intention-to-treat analysis included 
all eligible infants for whom consent had been 
provided. Exclusion criteria for the per-protocol 
analysis were determined prospectively (see Sec-
tion 4 in the Supplementary Appendix). Both 
analyses were performed without adjustment 
and with adjustment for gestational age, trial 
center, birth weight, exposure to antenatal gluco-
corticoids (<7 days before birth), and sex; analy-
ses with adjustment were designated as second-
ary analyses.
Secondary outcomes were analyzed on an 
intention-to-treat basis. A prespecified subgroup 
analysis according to gestational age (<34 weeks 
or ≥34 weeks) was performed for the primary 
outcome and selected secondary outcomes; hetero-
geneity was assessed by including an interaction 
term in the models. Since we did not prespecify 
a plan to adjust for multiple secondary out-
comes, we do not report P values for these 
outcomes.
For the primary outcome and dichotomous 
secondary outcomes, we calculated a risk differ-
ence (with a two-sided 95% confidence interval) 
in percentage points between the treatment 
groups. Since the widths of the confidence inter-
vals were not adjusted for multiple comparisons, 
the intervals should not be used to infer defini-
tive treatment effects for secondary outcomes. 
We used chi-square tests to compare dichoto-
mous outcomes, the appropriate parametric test 
(Student’s t-test) or nonparametric test (differ-
ence in medians estimated by quantile regres-
sion) to compare continuous outcomes, and 
generalized linear models for analyses with ad-
justment. All analyses were performed with the 
use of SAS software, version 9.4 (SAS Institute), 
or Stata software, version 14.0 (StataCorp).
An independent data and safety monitoring 
committee undertook a planned review of the 
primary outcome at the midpoint of the trial. 
Safety analyses for predefined serious adverse 
events, blinded to the intervention, were under-
taken after recruitment of 150 infants (20%), 
375 infants (50%), and 562 infants (75%).
R esult s
Recruitment
Infants were recruited from April 13, 2015, 
through November 28, 2017, at nine Australian 
nontertiary centers. The data and safety moni-
toring committee performed interim efficacy 
and safety reviews as planned and recommend-
ed that the trial continue unaltered.
Trial Patients
In total, 768 infants were randomly assigned to 
a treatment group (385 to the high-flow group 
and 383 to the CPAP group). Fourteen infants 
were excluded because they did not meet the eli-
gibility criteria or their parents did not provide 
consent or withdrew consent. A total of 754 
infants (mean gestational age, 36.9 weeks, and 
mean birth weight, 2909 g) were included in the 
primary intention-to-treat analysis (381 in the 
high-flow group and 373 in the CPAP group) and 
were followed until hospital discharge or death 
(Fig. 1). The demographic and clinical character-
istics of the mothers and infants included in the 
intention-to-treat analysis were similar in the 
two groups (Table 1). After exclusion of 77 in-
fants (42 in the high-flow group and 35 in the 
CPAP group), 677 infants were included in the 
Figure 1 (facing page). Numbers of Infants Who Were 
Screened, Assigned to a Trial Group, and Included  
in the Primary and Secondary Analyses.
Infants who were born at a gestational age of 31 weeks 
0 days or later, had a birth weight of at least 1200 g, 
and had a clinical diagnosis of respiratory distress were 
screened for eligibility. (Additional information regard‑
ing infants who did not meet the treatment‑failure cri‑
teria before respiratory support was escalated is pro‑
vided in Section 4 in the Supplementary Appendix). 
CPAP denotes continuous positive airway pressure.
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768 Underwent randomization
1415 Infants were assessed for eligibility
105 Were excluded (74 had one reason, 31 had
two reasons)
16 Had >2 hr of CPAP after admission
60 Underwent previous endotracheal 
intubation or had to undergo
immediate endotracheal intubation
11 Had known major congenital abnormality
49 Were transferred to another hospital
1310 Were eligible
542 Did not undergo randomization
295 Had parents who were not approached
for consent (290 were not approached for
one reason, 5 were not approached for
two reasons)
30 Had parents who were not approached
     for consent because staff were not
     available
38 Had parents who were unavailable to
     provide consent
25 Had parents with language barrier and
     interpreter was not available
84 Had parents who were not approached
     by clinician
68 Had other reason
55 Had unknown reason
6 Had parents who provided consent but
   did not undergo randomization
241 Had parents who declined to participate 
385 Were assigned to high-flow group 383 Were assigned to CPAP group
10 Were excluded
5 Underwent randomization
in error
4 Did not have consent
1 Had consent withdrawn
4 Were excluded
1 Underwent randomization
in error
2 Did not have consent
1 Had consent withdrawn
381 Were included in the 72-hr follow-up
after randomization and included
in the primary intention-to-treat analysis
373 Were included in the 72-hr follow-up
after randomization and included
in the primary intention-to-treat analysis
42 Were excluded from the per-
protocol analysis
18 Did not receive assigned
treatment
24 Were not treated
     according to treatment-
failure criteria protocol
35 Were excluded from the per-
protocol analysis
24 Did not receive assigned
treatment
11 Were not treated
     according to treatment-
failure criteria protocol
339 Were included in the per-protocol
analysis
338 Were included in the per-protocol
analysis
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per-protocol analysis (Fig. 1). The demographic 
characteristics of the per-protocol population 
are shown in Table S1 in the Supplementary Ap-
pendix.
Primary Outcome
In the intention-to-treat analysis, treatment fail-
ure within 72 hours after randomization occurred 
in 78 of the 381 infants (20.5%) randomly as-
signed to high-flow therapy and in 38 of the 373 
infants (10.2%) randomly assigned to CPAP (risk 
difference, 10.3 percentage points; 95% confi-
dence interval [CI], 5.2 to 15.4). High-flow ther-
apy was therefore not shown to be noninferior 
and, since zero was excluded from the 95% con-
fidence interval, CPAP was statistically superior 
(Table 2); a Kaplan–Meier survival curve of these 
data is shown in Figure S1 in the Supplementary 
Appendix. Results of adjusted analyses yielded 
similar results (Table 2). In the per-protocol 
analysis, treatment failure within 72 hours after 
randomization occurred in 49 of the 339 infants 
(14.5%) in the high-flow group and in 27 of the 
338 infants (8.0%) in the CPAP group (risk dif-
ference, 6.5 percentage points; 95% CI, 1.7 to 
11.2), also indicating that high-flow therapy was 
Characteristic
High-Flow Group 
(N = 381)
CPAP Group 
(N = 373)
Mothers
Age — yr 29.8±5.6 30.1±5.7
Multigravida — no. (%) 209 (54.9) 169 (45.3)
Use of antenatal glucocorticoids <7 days before birth — no. (%) 107 (28.1)  91 (24.4)
Labor — no. (%) 263 (69.0) 265 (71.0)
Cesarean section — no. (%) 204 (53.5) 177 (47.5)
Ruptured membranes ≥24 hr before delivery — no. (%)† 36 (9.4) 33 (8.8)
Chorioamnionitis — no. (%) 14 (3.7)  9 (2.4)
Meconium‑stained amniotic fluid — no. (%)  77 (20.2)  74 (19.8)
Infants
Gestational age
No. of weeks 36.9±2.8 36.9±3.0
<34 wk — no. (%)  72 (18.9)  68 (18.2)
Birth weight — g 2936±786 2885±790
Male sex — no. (%) 246 (64.6) 237 (63.5)
Multiple birth — no. (%) 26 (6.8) 37 (9.9)
Median Apgar score at 5 min (IQR)‡ 8.0 (7.0–9.0) 8.0 (7.0–9.0)
Treatment with CPAP before randomization§
No. of infants (%)  60 (15.7)  70 (18.8)
Median duration (IQR) — min 55.0 (30–90) 46.0 (28–70)
Blood gas analysis before randomization — no. (%) 216 (56.7) 209 (56.0)
pH¶ 7.20±0.09 7.20±0.09
Partial pressure of carbon dioxide — mm Hg‖ 64.5±14.1 63.8±14.4
Fraction of inspired oxygen before randomization** 26.9±9.6 27.5±11.6
*  Plus–minus values are means ±SD. There were no significant differences between the two groups, except in the mul‑
tigravida category (P<0.05). CPAP denotes continuous positive airway pressure, and IQR interquartile range.
†  Data on ruptured membranes were missing for one infant in the CPAP group.
‡  The 5‑minute Apgar score was not known for one infant in the high‑flow group and three infants in the CPAP group.
§  It was not known whether CPAP was used before randomization in one infant in the CPAP group.
¶  Data on pH were missing for one infant in the CPAP group.
‖  Data on the partial pressure of carbon dioxide were missing for one infant in the high‑flow group.
**  Data on the fraction of inspired oxygen were missing for two infants in the high‑flow group and two infants in the 
CPAP group.
Table 1. Baseline Characteristics of the Mothers and Infants.*
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not noninferior to CPAP. A Kaplan–Meier sur-
vival curve of the data for the per-protocol popu-
lation is shown in Figure S2 in the Supplemen-
tary Appendix.
A prespecified analysis according to gestational 
age showed similar findings in the two subgroups 
(Table 2) (P = 0.99 for the interactions in both 
the unadjusted and adjusted models). Post hoc 
sensitivity analyses excluding infants who received 
CPAP before randomization yielded similar results 
(Table S4 in the Supplementary Appendix). A 
small percentage of infants who underwent ran-
domization in the intention-to-treat population 
(3.7%) were twin pairs who underwent random-
ization individually; results of a post hoc sensi-
tivity analysis excluding these infants are shown 
in Table S5 in the Supplementary Appendix.
Secondary Outcomes and Adverse Events
All secondary outcomes and adverse events are 
presented for the intention-to-treat population. 
The secondary outcome for the per-protocol 
population (transfer to a tertiary-level NICU) is 
included in Table S2 in the Supplementary Ap-
pendix.
Secondary outcomes and adverse events are 
listed in Table 3. The reasons for treatment fail-
ure are listed in Table S6 in the Supplementary 
Appendix. The most common reason for treat-
ment failure in the two trial groups was a frac-
tion of inspired oxygen of at least 0.40 for more 
than 1 hour. Treatment failure due to apnea oc-
curred more frequently in the high-flow group 
than in the CPAP group. The most common 
other reason for treatment failure in the high-
flow group was escalation of therapy in infants 
in whom the criteria for treatment failure had 
not been met (in 17 of 23 infants). In the CPAP 
group, the most common other reason for treat-
ment failure was pneumothorax (in 8 of 11 in-
fants).
Of the 78 infants in the high-flow group in 
whom treatment failure occurred, 62 infants 
received backup CPAP during the primary out-
come period, and 32 were not intubated or 
transferred to a NICU within 72 hours after 
randomization. The incidences of mechanical 
ventilation and transfer to a NICU did not differ 
significantly between the groups. The median 
duration of respiratory support and the median 
Outcome
All 
 Patients
High-Flow Group 
(N = 381)
CPAP Group 
(N = 373) Risk Difference (95% CI)†
Univariate 
 Analysis
Adjusted 
 Analysis‡
no. no./total no. (%)
Intention-to-treat analysis
Treatment failure within 72 hr 
 after randomization
754 78/381 (20.5) 38/373 (10.2) 10.3 (5.2 to 15.4)§ 9.2 (3.9 to 14.5)
Gestational age <34 wk 140 20/72 (27.8) 12/68 (17.6) 10.1 (−3.6 to 23.9) 8.7 (−5.8 to 23.1)
Gestational age ≥34 wk 614 58/309 (18.8) 26/305 (8.5) 10.3 (4.9 to 15.6)§ 8.3 (2.7 to 14.0)
Per-protocol analysis
Treatment failure within 72 hr 
 after randomization
677 49/339 (14.5) 27/338 (8.0) 6.5 (1.7 to 11.2) 5.5 (0.5 to 10.4)
Gestational age <34 wk 129 14/65 (21.5) 10/64 (15.6) 5.9 (−7.5 to 19.3) 6.0 (−8.0 to 19.9)
Gestational age ≥34 wk 548 35/274 (12.8) 17/274 (6.2) 6.6 (1.7 to 11.5) 5.5 (0.2 to 10.7)
*  P = 0.99 for the interaction in the intention‑to‑treat analysis and P = 0.93 for the interaction in the per‑protocol analysis (both unadjusted). 
On the basis of a noninferiority margin of 10 percentage points, high‑flow therapy was not noninferior to CPAP in all analyses. CI denotes 
confidence interval.
†  Apart from the primary analysis (univariate intention‑to‑treat analysis for all infants), other differences in risk are secondary outcomes that 
were not adjusted for multiple outcomes, and inferences drawn from these intervals may not be reproducible.
‡  The analysis was adjusted for stratification variables (gestational‑age group and trial center) and prespecified confounders (birth weight, ex‑
posure to antenatal glucocorticoids, and sex). Data from hospitals with a low incidence of treatment failure were aggregated before control‑
ling for trial center in all per‑protocol analyses and for the intention‑to‑treat analysis involving infants younger than 34 weeks of gestational 
age; different levels of aggregation were used in each analysis (see Section 6 and Table S3 in the Supplementary Appendix).
§  P<0.001.
Table 2. Primary Outcome in the Intention-to-Treat and Per-Protocol Analyses.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on June 4, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 380;21 nejm.org May 23, 20192038
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Outcome
High-Flow Group 
(N = 381)
CPAP Group 
(N = 373) Difference (95% CI)†
percentage points
Mechanical ventilation through an endotracheal tube — no. (%)
<72 hr after randomization 21 (5.5) 22 (5.9) −0.4 (−3.7 to 2.9)
At any time after randomization 25 (6.6) 22 (5.9) 0.7 (−2.8 to 4.1)
Transfer to tertiary NICU — no. (%)‡
<72 hr after randomization 39 (10.2) 32 (8.6) 1.7 (−2.5 to 5.8)
At any time after randomization 49 (12.9) 41 (11.0) 1.9 (−2.8 to 6.5)
Surfactant treatment <72 hr after randomization — no. (%) 21 (5.5) 22 (5.9) −0.4 (−3.7 to 2.9)
Median no. of hr of respiratory support after randomization (IQR) 20 (10 to 48) 15 (7 to 35) 5.0 (1.5 to 8.5)
Median no. of hr of supplemental oxygen (IQR) 5 (0 to 18) 1 (0 to 14) 4.0 (2.1 to 5.9)
Final respiratory diagnosis — no. (%)§
Transient tachypnea of the newborn 169 (44.4) 160 (42.9) NC
Respiratory distress syndrome 161 (42.3) 162 (43.4) NC
Pneumothorax 4 (1.1) 11 (2.9) NC
Other 47 (12.3) 40 (10.7) NC
Full breast‑feeding at hospital discharge — no. (%) 163 (42.8) 155 (41.6) 1.2 (−5.8 to 8.3)
Median no. of days of intravenous fluids after randomization (IQR) 3 (2 to 5) 3 (2 to 5) 0.0 (−0.3 to 0.3)
Median age at start of full‑suck feeding (IQR)¶ 4 (2 to 13) 4 (2 to 14) 0 (−1.2 to 1.2)
Weight gain from birth to final hospital discharge — g/kg/day −2.4±9.2 −1.9±9.1 −0.5 (−1.8 to 0.8)
Median no. of days in hospital (IQR)
Total no. of days in any hospital 7 (3 to 18) 7 (4 to 17) 0 (−2.2 to 2.2)
Tertiary NICU‖ 6.9 (5.0 to 11.5) 5.8 (3.3 to 11.8) 1.1 (−2.1 to 4.3)
Death before hospital discharge — no. (%)**,†† 2 (0.5) 0 0.5 (−0.2 to 1.3)
Supplemental oxygen or respiratory support
At 28 days of life; born ≥32 wk gestational age‡‡ 2 (0.5) 0 0.5 (−0.2 to 1.3)
At 36 wk postmenstrual age; born <32 wk gestational age§§ 0 0 NC
Pneumothorax diagnosed after randomization
Any 23 (6.0) 28 (7.5) −1.5 (−5.1 to 2.1)
Drained with needle thoracocentesis or intercostal catheter** 9 (2.4) 18 (4.8) −2.5 (−5.1 to 0.2)
Nasal trauma after randomization 2 (0.5) 6 (1.6) −1.1 (−2.6 to 0.4)
*  Plus–minus values are means ±SD. NC denotes not calculated, and NICU neonatal intensive care unit.
†  Differences were calculated as the difference in percentages for dichotomous data or as the difference in medians or means for continu‑
ous data. These differences have not been adjusted for multiple comparisons, and inferences drawn from these intervals may not be re‑
producible.
‡  This category includes decisions made by a clinician after treatment failure to transfer an infant to a NICU.
§  This outcome was not included in the original statistical analysis plan, but it was added as a post hoc comparison. The final respiratory di‑
agnosis was based on the discharge summary provided by the clinician who was caring for the infant. Cases in which there were major in‑
consistencies between the clinical course and the recorded diagnosis were reviewed by the investigators and clinicians who were unaware 
of the treatment group, and a diagnosis was reached by consensus.
¶  The age at the start of full‑suck feeding was missing for 10 infants in the high‑flow group and 4 infants in the CPAP group.
‖  Data shown are for 49 infants in the high‑flow therapy group and 41 infants in the CPAP group who were admitted to a NICU at any time 
before final discharge.
**  These events were specified as serious adverse events in the trial.
††  Both deaths occurred after 1 month of age in association with genetic conditions; these deaths were determined by the investigators to be 
unrelated to the trial intervention.
‡‡  Data shown are for 731 infants (368 in the high‑flow group and 363 in the CPAP group); 7 infants were never assessed (4 in the high‑flow 
group and 3 in the CPAP group).
§§  Data shown are for 16 infants (9 in the high‑flow group and 7 in the CPAP group); all infants were assessed.
Table 3. Secondary Outcomes and Adverse Events.*
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number of hours after birth at which supple-
mental oxygen was discontinued were higher in 
the high-flow group than in the CPAP group. 
The incidence of adverse events did not differ 
significantly between the groups (Table 3).
There were no significant differences in the 
calculated mean costs of nontertiary special care 
nursery hospital stays, tertiary NICU stays, or 
interhospital transfers between the two groups. 
More information is provided in Section 3 in the 
Supplementary Appendix.
Discussion
In this multicenter, randomized trial comparing 
two types of primary respiratory support for 
newborn infants in nine Australian nontertiary 
special care nurseries, high-flow treatment was 
not shown to be noninferior to CPAP for pre-
venting treatment failure within the first 72 
hours after randomization in the primary inten-
tion-to-treat analysis or in the secondary per-
protocol analysis. Both analyses suggested that 
CPAP was superior to high-flow therapy.
High-flow therapy was successful in approxi-
mately 80% of the infants and, with CPAP avail-
able as backup treatment when primary high-
flow therapy failed, there was no increase in the 
need for mechanical ventilation or NICU trans-
fer or in adverse events. It is plausible that the 
use of backup CPAP was responsible for avoiding 
intubation or NICU transfer in up to 32 of 78 
infants (41%) in the high-flow group with treat-
ment failure. Our previous noninferiority studies 
of high-flow therapy in preterm infants also 
showed that the use of backup CPAP prevented 
intubation in almost half the infants in whom 
high-flow treatment failure occurred.11,15 Infants 
in the high-flow group received respiratory sup-
port for a median of 5 hours longer and supple-
mental oxygen for a median of 4 hours longer 
than the infants in the CPAP group, but the 
clinical importance of these differences is un-
certain. Interpretation of these results may vary 
according to the circumstances of individual 
treatment centers. Important considerations in-
clude the number of staff, staff expertise, and 
the distances to treatment centers offering me-
chanical ventilation. Although high-flow therapy 
was not noninferior, the facts that CPAP served 
as effective backup therapy and that many infants 
were successfully treated with high-flow therapy 
mean that these results may not preclude a role 
for high-flow therapy in treating some newborn 
infants.
We included infants born at 31 weeks of ges-
tational age or later, with a birth weight of at 
least 1200 g; this population was representative 
of the usual population cared for in Australian 
nontertiary special care nurseries. The results of 
this trial are consistent with those of previous 
randomized trials comparing high-flow therapy 
with CPAP as early respiratory support for pre-
term infants in NICUs who have not received 
exogenous surfactant treatment.18,19
A previous noninferiority trial11 involving pre-
term infants born at 28 to 36 weeks of gestation 
and cared for in tertiary-level NICUs was discon-
tinued early when CPAP was shown at the interim 
analysis to be superior to high-flow therapy at 
preventing treatment failure. That trial also 
showed that the use of high-flow therapy in 
conjunction with rescue CPAP did not result in 
important adverse outcomes. It is possible that 
inconsistent generation of distending pressures 
with high-flow therapy may account for the dif-
ference in the incidence of treatment failure.20-23 
Other studies comparing high-flow therapy with 
CPAP as primary respiratory support for preterm 
infants have shown little difference between the 
treatments,24,25 but this may be explained by the 
use of exogenous surfactant before determina-
tion of the primary outcome. Administration of 
exogenous surfactant is unlikely to be generaliz-
able to special care nurseries, where it is chal-
lenging for clinicians to maintain the skills re-
quired for delivery of surfactant.
Blinding of the intervention in our trial was 
not possible. To minimize bias, we used pre-
specified, objective criteria to determine the 
primary outcome. The use of backup CPAP may 
have influenced the incidences of secondary 
outcomes in the high-flow group. We took a 
pragmatic approach of including infants who 
had received up to 2 hours of CPAP before ran-
domization. Post hoc sensitivity analyses exclud-
ing these infants did not show a material differ-
ence in the results.
In conclusion, in this trial with a margin of 
noninferiority of 10 percentage points, we found 
that high-flow therapy was not noninferior to 
CPAP. High-flow therapy resulted in a signifi-
cantly higher incidence of treatment failure than 
CPAP when used as early respiratory support for 
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newborn infants with respiratory distress in non-
tertiary special care nurseries.
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